[HTML][HTML] Cinacalcet for Symptomatic Hypercalcemia Caused by AP2S1 Mutations

SA Howles, FM Hannan, VN Babinsky… - … England Journal of …, 2016 - Mass Medical Soc
SA Howles, FM Hannan, VN Babinsky, A Rogers, CM Gorvin, N Rust, T Richardson…
New England Journal of Medicine, 2016Mass Medical Soc
Cinacalcet for Symptomatic Hypercalcemia Caused by AP2S1 Mutations | NEJM Skip to main
content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to
become a physician, build your knowledge, lead a health care organization, and advance your
career with NEJM Group information and services. NEJM Evidence NEW! A digital journal for
innovative original research and fresh, bold ideas in clinical trial design and clinical
decision-making. NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to …
The authors show that cinacalcet, which mediates allosteric modulation of the calcium-sensing receptor, corrects loss of function of AP2S1 mutations that cause familial hypocalciuric hypercalcemia type 3 and ameliorates symptomatic hypercalcemia.
The New England Journal Of Medicine